Correlation Between Contineum Therapeutics, and Humacyte

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Contineum Therapeutics, and Humacyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Contineum Therapeutics, and Humacyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Contineum Therapeutics, Class and Humacyte, you can compare the effects of market volatilities on Contineum Therapeutics, and Humacyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Contineum Therapeutics, with a short position of Humacyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Contineum Therapeutics, and Humacyte.

Diversification Opportunities for Contineum Therapeutics, and Humacyte

-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Contineum and Humacyte is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Contineum Therapeutics, Class and Humacyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Humacyte and Contineum Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Contineum Therapeutics, Class are associated (or correlated) with Humacyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Humacyte has no effect on the direction of Contineum Therapeutics, i.e., Contineum Therapeutics, and Humacyte go up and down completely randomly.

Pair Corralation between Contineum Therapeutics, and Humacyte

Given the investment horizon of 90 days Contineum Therapeutics, Class is expected to generate 0.6 times more return on investment than Humacyte. However, Contineum Therapeutics, Class is 1.66 times less risky than Humacyte. It trades about 0.22 of its potential returns per unit of risk. Humacyte is currently generating about -0.02 per unit of risk. If you would invest  600.00  in Contineum Therapeutics, Class on August 5, 2025 and sell it today you would earn a total of  501.00  from holding Contineum Therapeutics, Class or generate 83.5% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy98.46%
ValuesDaily Returns

Contineum Therapeutics, Class  vs.  Humacyte

 Performance 
       Timeline  
Contineum Therapeutics, 

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Contineum Therapeutics, Class are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Contineum Therapeutics, displayed solid returns over the last few months and may actually be approaching a breakup point.
Humacyte 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Contineum Therapeutics, and Humacyte Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Contineum Therapeutics, and Humacyte

The main advantage of trading using opposite Contineum Therapeutics, and Humacyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Contineum Therapeutics, position performs unexpectedly, Humacyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will offset losses from the drop in Humacyte's long position.
The idea behind Contineum Therapeutics, Class and Humacyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Complementary Tools

Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation